<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03775928</url>
  </required_header>
  <id_info>
    <org_study_id>LB</org_study_id>
    <nct_id>NCT03775928</nct_id>
  </id_info>
  <brief_title>Compare Apatinib Plus Capecitabine Versus Capecitabine in Maintenance Therapy for Patients With Advanced Triple-negative Breast Cancer</brief_title>
  <official_title>Phase Ⅱ Study of Compare Apatinib Plus Capecitabine Versus Capecitabine in Maintenance Therapy for Patients With Advanced Triple-negative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy and safety of patients who receive&#xD;
      apatinib plus capecitabine or capecitabine for maintenance therapy of patients with with&#xD;
      advanced triple-negative breast cancer&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Triple-negative breast cancer (TNBC) has the characteristics of early onset, high malignancy,&#xD;
      less treatment, and resistance to treatment. Advanced patients have shorter survival than&#xD;
      other subtypes. Maintenance therapy after combination chemotherapy can prolong the disease&#xD;
      control time in patients with advanced TNBC. How to prolong the disease control time of&#xD;
      patients with advanced TNBC without affecting the quality of life has become the focus of&#xD;
      current research.&#xD;
&#xD;
      Anti-angiogenic drugs are currently one of the few targeted therapies that have achieved some&#xD;
      efficacy in TNBC. Apatinib, a targeted inhibitor of VEGF receptor 2 (VEGFR2), shows&#xD;
      significant antitumor activity in the patients with breast cancer. The results of this study&#xD;
      will help explore the new treatment of small molecule anti-angiogenic drugs for TNBC&#xD;
      maintenance therapy, and provide some new ideas for improving individualized treatment&#xD;
      options for patients with advanced TNBC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Anticipated">December 18, 2018</start_date>
  <completion_date type="Anticipated">October 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>up to 6 months</time_frame>
    <description>Time from randomization to disease progression or death for any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>up to 6 months</time_frame>
    <description>Time from randomization to death for any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tine to progress</measure>
    <time_frame>up to 6 months</time_frame>
    <description>Time from randomization to disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>up to 6 months</time_frame>
    <description>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Triple-negative Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Apatinib + Capecitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apatinib 425mg d1-21+ capecitabine 1000mg/m2 bid d1-14, q21d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Capecitabine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>capecitabine 1000mg/m2 bid d1-14, q21d</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib</intervention_name>
    <description>apatinib 425mg qd po</description>
    <arm_group_label>Apatinib + Capecitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
    <description>capecitabine 1000mg/m2 bid d1-d14</description>
    <arm_group_label>Apatinib + Capecitabine</arm_group_label>
    <arm_group_label>Capecitabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age：18~75 years;&#xD;
&#xD;
          2. Triple-negative breast cancer (TNBC) confirmed by histology examination;&#xD;
&#xD;
          3. patients had received first-line combination chemotherapy for advanced metastatic&#xD;
             disease, and had a complete response, partial response or stable disease according to&#xD;
             Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria;&#xD;
&#xD;
          4. received endocrine therapy for metastatic disease before first-line chemotherapy were&#xD;
             allowed;&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1;&#xD;
&#xD;
          6. A life expectancy of more than 12 weeks;&#xD;
&#xD;
          7. Baseline blood routine examination in accordance with the following criteria :&#xD;
             ANC≥1.5×109/L，PLT≥90×109/L，Hb≥90g/L;&#xD;
&#xD;
          8. Liver and renal function in accordance with the following criteria: total bilirubin&#xD;
             less than 1.5 times the upper limit of normal value; aspartate aminotransferase (AST),&#xD;
             or alanine aminotransferase (ALT) less than 2.5 times the upper limit of normal value,&#xD;
             less than 5 times the upper limit of normal value in patients with liver metastases.&#xD;
&#xD;
             the creatinine clearance rate calculated greater than 60 mL/min;&#xD;
&#xD;
          9. Females of childbearing potential must be a pregnancy test in 7 days before&#xD;
             participating ( including serum or urine), and the results were negative, and they are&#xD;
             willing to take effective contraceptive methods During the trial and within 8 weeks&#xD;
             after the last dose;&#xD;
&#xD;
         10. Obtain informed consent from patients before starting any research-related operations&#xD;
             and treatments to confirm that patients are willing to participate in this study and&#xD;
             comply with research-related requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Metastasis/recurrence occurs within 6 months of adjuvant chemotherapy;&#xD;
&#xD;
          2. controlled high blood pressure, systolic blood pressure ≥150mmHg or diastolic blood&#xD;
             pressure ≥100mmHg;&#xD;
&#xD;
          3. urine routine test with urinary protein more than ++, or 24 hour urinary protein more&#xD;
             than 1.0 g;&#xD;
&#xD;
          4. abnormal coagulation function (INR &gt; 1.5 or prothrombin time (PT) &gt; ULN+4 seconds or&#xD;
             APTT &gt;1.5 times the ULN);&#xD;
&#xD;
          5. Pregnant or lactating woman;&#xD;
&#xD;
          6. Symptomatic brain parenchymal and/or pia mater metastases without treatment and&#xD;
             control;&#xD;
&#xD;
          7. Patients with Other malignant tumors in the past 5 years, except for fully treated&#xD;
             cervical carcinoma in situ, cutaneous squamous cell carcinoma or well-controlled&#xD;
             localized basal cell skin cancer;&#xD;
&#xD;
          8. Mental illness or other condition that affects patient compliance;&#xD;
&#xD;
          9. serious and uncontrollable systemic diseases (eg clinically significant cardiovascular&#xD;
             disease, lung or metabolic disease, arteriovenous thrombosis, etc.) happened recently;&#xD;
&#xD;
         10. Can not take or absorb oral drugs;&#xD;
&#xD;
         11. Receiving any other testing drugs, or participating in other clinical trial 30 days&#xD;
             before being enrolled in this trial;&#xD;
&#xD;
         12. The patient has previously received treatment with an anti-angiogenic drug (whether&#xD;
             adjuvant or palliative);&#xD;
&#xD;
         13. Known or suspected to be allergic to any research drug or excipient;&#xD;
&#xD;
         14. Any other researcher believes that it is not appropriate to participate in this test.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Binghe Xu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Binghe Xu</last_name>
    <phone>86-87788826</phone>
    <phone_ext>861087788120</phone_ext>
    <email>xubinghe@medmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bo Lan</last_name>
    <phone>86-87788114</phone>
    <phone_ext>861087788120</phone_ext>
    <email>daxiaolanbo@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cancer hospital, ChineseAMS</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Binghe Xu, PhD</last_name>
      <phone>86-10-87788826</phone>
      <email>xubinghe@medmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Bo Lan, PhD</last_name>
      <phone>86-10-87788114</phone>
      <email>daxiaolanbo@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Binghe Xu, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fei Ma, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bo Lan, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>December 13, 2018</study_first_submitted>
  <study_first_submitted_qc>December 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2018</study_first_posted>
  <last_update_submitted>December 13, 2018</last_update_submitted>
  <last_update_submitted_qc>December 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Ma Fei，MD</investigator_full_name>
    <investigator_title>clinical professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

